- About 20% of all MRI examinations are subject to patient movement, costing over $1B/year in rescans across 11,000 MRI machines in North America.
- MotionCorrect makes MRI scans simpler and shorter for patients by using a visual tracking system to compensate for movement in real-time.
- Our platform increases MRI efficiency and effectiveness by allowing the incorporation of cutting-edge scanning sequences.
- By increasing image quality, augmenting diagnostic accuracy and reducing re-scans, we improve patient care and throughput.
- We offer a comprehensive, NIH-patented real-time solution, combining off-the-shelf cameras with tracking and scanning optimization software that interfaces with OEM’s MRI platforms.
- Our only competitor is at the pre-FDA approval startup stage and provides a single-camera solution with reduced accuracy but simpler setup.
- We are a low cost, highly scalable software system company.
- Our service agreement provides low entry cost and peace of mind.
- A capital expense model will also be available.
- Through future add-ons, we will expand our value proposition beyond motion correction.
- 2015 and 2016: polish the product, establish alpha sites and begin clinical trials;
- 2017: submit to FDA and expand beta sites;
- 2018 and 2019: obtain FDA approval and launch;
- 2025: reach 20% market share.
- Montreal is uniquely suited with its world renowned research centers in neuroimaging. Our R&D team has ties with the Montreal Neurological Institute, Douglas Institute, and l’Unité de Neuroimagerie Fonctionnelle.
- We will collaborate with clinics specialized in pediatric, geriatric care, and sports medicine, such as Montreal Children’s Hospital, Sainte-Justine, Concordia’s PERFORM.
- We will work with MRI OEMs to ensure compatibility and ease of integration.
- Current team composition:
- MRI R&D;
- Medicine and clinical care;
- Real-time robotic vision;
- Licensing and IP;
- Forensic accounting;
- Contract negotiation.
- Planned expertise:
- Three full-time developers;
- One imaging specialist;
- One clinical research coordinator;
- FDA approval consulting services.
- We are raising $2M to develop and clinically validate our prototype for FDA submission by 2017.
- Half of the funding will go towards product R&D, while the other half will go towards clinical trials and fulfilling FDA application requirements.